Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apexigen raises $73m to advance immuno-oncology product development
The $15m Series B financing was led by Decheng Capital and the recent $58m Series C financing was led by 3E Bioventures Capital, Virtus Inspire Ventures, and SV
The $15m Series B financing was led by Decheng Capital and the recent $58m Series C financing was led by 3E Bioventures Capital, Virtus Inspire Ventures, and SV
Poseida will apply UniDab binders, which demonstrate significant advantages over traditional single chain variable antibody fragment (scFv) binders, to the development of its next generation CAR-T therapies. The
The company will pay the amount to clear two whistleblower lawsuits brought by the state of Texas under the Texas Medicaid Fraud Prevention Act (TMFPA). Under the first
Cystic fibrosis (CF) is characterized by abnormal ion transport in the apical membrane of epithelial cells. The partnership will use a novel and replication deficient lentiviral vector in
Neuren retains rights to develop and commercialize trofinetide for all indications outside of North America. ACADIA plans to initiate a Phase 3 randomized, double-blind placebo-controlled study evaluating trofinetide
AstraZeneca licensed selumetinib from Array BioPharma in 2003. AstraZeneca and Merck have entered a co-development and co-commercialisation agreement for selumetinib in 2017. NF1 is an incurable genetic condition,
Under the terms of the agreement, Juvenescence will purchase, in a single transaction, 14.4 million shares of AgeX Therapeutics from BioTime for $43.2 million. 50% of the purchase
Amgen is evaluating AMG 890 in a Phase 1 clinical study designed to assess its safety in volunteers with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has
Acebilustat is a small molecule inhibitor of Leukotriene A4 Hydrolase (LTA4H), the crucial enzyme in the production of the potent inflammatory mediator Leukotriene B4 (LTB4). The anti-inflammatory drug
The new location joins Sydney and Brisbane as the third Australian hub and solidifies the company’s position as the leader in Australia for clinical trial supply chain solutions.